SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Roy Glen who wrote (20674)5/13/1998 12:22:00 PM
From: Henry Niman  Respond to of 32384
 
Evista and other SERMs are anti-estrogens as is Tamoxifen. Tamoxifen is the standard (FDA approved) hormone treatment for prevention of re-occurance of breast cancer. Droloxifene (PFE's SERM that LGND gets royalties on) completed a Phase III clinical trial for treating breast cancer but the data was similar to Tamoxifen, so the indication was not filed (see home.att.net for press release of 1/22/98).